Which drug first? Real-World study aims to optimize colorectal cancer treatment sequence
NCT ID NCT05839951
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed observational study examined the real-world use of two approved drugs, regorafenib and TAS-102 (sometimes with bevacizumab), in 818 adults with metastatic colorectal cancer that had stopped responding to other treatments. Researchers analyzed electronic health records to see how the order of these drugs affected treatment duration, side effects, and survival. The goal is to provide practical guidance for doctors on the best sequence to use in everyday practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Regorafenib, TAS-102 (trifluridine/tipiracil), and bevacizumab
- What this could lead to
- If successful, this study could help doctors choose the best order of these approved drugs for people with advanced colorectal cancer, potentially improving survival and quality of life.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient differences and real-world variability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Many locations
Whippany, New Jersey, 07981, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vitamin b derivative boost chemo for advanced colon cancer?
- Exercise may boost Well-Being in advanced colorectal cancer patients
- Real-World study tests fruquintinib for Tough-to-Treat colorectal cancer
- New pill combo aims to tackle Hard-to-Treat colorectal cancer
- Can a targeted drug keep working after cancer progresses? new trial aims to find out
- Promising drug duo targets Hard-to-Treat HER2 cancers